GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Price-to-Funds-From-Operations

Alimera Sciences (STU:ASZ1) Price-to-Funds-From-Operations : (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Alimera Sciences (STU:ASZ1) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.